ArticleCureus2025
Serum 25(OH)D Levels in Fragility-Fractured and Non-fractured Patients in a Low Latitude Region.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVitamin D is produced in nature in two main forms: vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). The measurement of serum 25(OH)D is the most accurate way to determine the amount of vitamin D in an individual. The association between 25(OH)D and fragility fractures (FxF) has been recognized for many years, but its direct role is unclear.
objectivesThis study aimed to assess the association between serum 25(OH)D levels and FxF in a hospital-based population in the Colombian Caribbean (latitude ~10.3°), using a cross-sectional design with prospective data collection, while adjusting for confounders such as age, sex, skin phototype, BMI, grip strength, and comorbidities. Secondary objectives included exploring potential effect modification by skin phototype and describing the prevalence of vitamin D insufficiency in this low-latitude cohort.
methodsA cross-sectional study with prospective data collection was performed comparing serum 25(OH)D levels between FxF and non-fractured (non-FxF) patients. Logistic regression, adjusted for age and sex, identified clinical characteristics associated with FxF. Results: Forty patients with FxF were compared with 40 non-FxF participants. Women comprised 89% of the FxF group. The median age in FxF was 73 years (interquartile range (IQR) 62-80) and 75 years in non-FxF (IQR 62-80; p = 0.2037). Phototype III skin was most common and acted as a protective factor against FxF with a crude odds ratio (OR) of 0.29 (95% CI: 0.19-0.84; p = 0.011) and an adjusted OR of 0.27 (95% CI: 0.12-0.89; p = 0.015). No statistically significant differences in 25(OH)D levels were found between groups (FxF: 26.0 + 10.0 ng/mL; non-FxF: 26.9 + 10.3 ng/mL; p = 0.6991).
conclusionsBoth FxF and non-FxF patients showed insufficient 25(OH)D levels, echoing findings from Mendelian randomization studies suggesting no causal link between low vitamin D and FxF. Phototype III was the most common and was found to be protective. Phototypes V and VI were not observed in the study cohort. The inclusion of the hospital-based nature of the cohort may explain the overall vitamin D insufficiency and higher grip strength in the group with FxF. Further studies are required to assess the interaction of genetic and metabolic factors in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.